All In Biotech

Drug Trial Radar · NCT03117894

PECS-2 for Breast Surgery

Regional Anesthesia for Breast Cancer Surgery, Effects on Postoperative Wellbeing and Disease Recurrence.

Last checked: Nov 20, 2026Latest source record: Jun 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

May 23, 2017

Primary completion

Oct 22, 2020

Study completion Oct 22, 2020

Sponsor

Lead sponsor
Umeå UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is no consensus regarding which alternative is the best anesthesia for breast surgery, general anesthesia and morphine for postoperative analgesia or a combination of regional anesthesia and general anesthesia that possibly attenuates or abolishes the need for morphine. The current study aims to determine which of the two strategies that is best in relation to postoperative pain, nausea and risk of recurrence of the disease.

Conditions

  • Breast Neoplasm Female
  • Regional Anesthesia
  • Anesthesia
  • Regional Anesthesia Morbidity
  • Anesthesia Morbidity

Interventions

  • Ropivacaine 5 mg/ml, 35 mlDrug

    Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.

  • Remifentanil 50 microg/mlDrug

    The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

  • Betamethason 4 mgDrug

    Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.

  • Paracetamol 1,5 gDrug

    Administered preoperatively to prevent pain postoperatively.

  • PropofolDrug

    The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

  • Arcoxia, 120 mgDrug

    Administered preoperatively to prevent pain postoperatively.

  • Ondansetron 4 mgDrug

    Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.

  • MorphineDrug

    Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Opiate consumptionTime frame: 48 hours
  2. All cause mortalityTime frame: 3 years and 5 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Östersund Hospital

    Östersund, Jämtland County, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.